Dacomitinib (PF-299804) is a second-generation, irreversible pan-ErbB inhibitor with IC50s of 6 nM (EGFR), 45.7 nM (ERBB2), and 73.7 nM (ERBB4). It binds irreversibly to the ATP site of ErbB receptors and exhibits antitumor activity, ranging from tumor growth delay to regression in xenograft models, including those resistant to first-generation ErbB inhibitors. Reagent grade, for research use only.
Usually ships within 24 hours.